Here are the S-3 shelf registrations from COMPASS Pathways Plc (CMPS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow CMPS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CMPS filings page.
Compass Pathways plc filed an automatic Form S‑3 shelf registration as a well‑known seasoned issuer, enabling flexible primary offerings of an indeterminate amount of ordinary shares (including ADSs), debt securities, warrants, and units, as well as secondary resales. A separate resale prospectus covers the potential resale of up to 10,649,700 ordinary shares or ADSs by named selling security holders, from which Compass will not receive proceeds. As of June 30, 2026, ordinary shares outstanding were 135,722,306, with 23,848,829 pre‑funded warrants outstanding, each exercisable for one ADS at $0.0001 per ADS. The company highlights advanced clinical progress for its COMP360 psilocybin program in treatment‑resistant depression, including positive Phase 3 results, FDA rolling review of its NDA, and award of a National Priority Voucher, and is initiating a Phase 2b/3 trial in PTSD.